Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases |
Aziz, Ashraf Omar Abdel
(Department of Endemic Medicine and Hepatogastroenterology, National Cancer Institute, Cairo University)
Omran, Dalia (Department of Endemic Medicine and Hepatogastroenterology, National Cancer Institute, Cairo University) Nabeel, Mohamed Mahmoud (Department of Endemic Medicine and Hepatogastroenterology, National Cancer Institute, Cairo University) Elbaz, Tamer Mahmoud (Department of Endemic Medicine and Hepatogastroenterology, National Cancer Institute, Cairo University) Abdelmaksoud, Ahmed Hosni (Department of Diagnostic and Interventional Radiology, Faculty of Medicine, National Cancer Institute, Cairo University) Attar, Inas El (Department of Biostatistics and Cancer Epidemiology, National Cancer Institute, Cairo University) Shousha, Hend Ibrahim (Department of Endemic Medicine and Hepatogastroenterology, National Cancer Institute, Cairo University) |
1 | Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. DOI |
2 | Cabibbo G, Genco C, Di Marco V, et al (2011). Predicting survival in patients with hepatocellular carcinoma treated by transarterialchemoembolisation. Aliment Pharmacol Ther, 34, 196-204 DOI |
3 | European Association For The Study Of The LiverEuropean Organization For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 56, 908-43. DOI |
4 | Gomaa AI, Hashim MS, Waked I (2014). Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One, 9, 90929. DOI |
5 | Greten TF, Wang XW, Korangy F (2015). Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut, 64, 842-8 DOI |
6 | Hsu CY, Lee YH, Hsia CY, et al (2013). Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatol, 57,112-9. DOI |
7 | Hsu CY, Liu PH, Lee YH, et al (2015). Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis. Ann Surg Oncol, 22, 1324-31. |
8 | Kim BK, Kim SU, Park JY, et al (2012). Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single-centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int, 32, 1120-7. DOI |
9 | Kudo M, Osaki Y, Matsunaga T, et al (2013). Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis, 31, 490-8. DOI |
10 | Lee YH, Hsia CY, Hsu CY, et al (2013). Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg, 37, 1348-55. DOI |
11 | Lee YH, Hsu CY, Huo TI (2013). Assessing liver dysfunction in cirrhosis: role of the model for end-stage liver disease and its derived systems. J Chin Med Assoc, 76, 419-24. DOI |
12 | Liu PH, Lee YH, Hsia CY, et al (2014). Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol, 21, 1825-33 DOI |
13 | Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. DOI |
14 | Llovet JM, Ricci S, Hilgard P, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. DOI |
15 | Mittal S, El-Serag HB (2013). Epidemiology of hepatocellular carcinoma consider the population. J ClinGastroenterol 47, 2-6. |
16 | Ruzzenente A, Capra F, Pachera S, et al (2009). Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg, 13, 1313-20 DOI |
17 | Nuzzo G, Vauthey JN, Choti MA, et al (2013). A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg, 257, 929-937 DOI |
18 | Omran D A, Awad A H, Mabrouk M A, et al (2015). Application of data mining techniques to explore predictors of HCC in Egyptian patients with HCV-related chronic liver disease. Asian Pac J Cancer Prev, 16, 23-27 DOI |
19 | Poon RT, Fan ST, Tsang FH, Wong J (2002). Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg, 235, 466-486 DOI |
20 | Poon D, Anderson BO, Chen LT, et al (2009). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol, 10, 1111-8 DOI |
21 | Shaker MK, Abdella HM, Khalifa MO, El Dorry AK (2013) Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int, 33, 1601-6. |
22 | Strickland GT, Elhefni H, Salman T, et al (2002). Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg, 67, 436-42. DOI |
23 | Tokushige K, Hashimoto E, Yatsuji S, et al (2010). Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol, 45, 960-7. DOI |
24 | Yau T, Tang VY, Yao TJ, et al (2014). Development of Hong Kong Liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterol, 146, 1691-700. DOI |
25 | Yang T, Lau WY, Zhang H, et al (2015). Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective. World J Gastroenterol, 21, 8256-61 DOI |